Tandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of ($0.40), $0.11 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $29.1 million versus the consensus estimate of $29.17 million.

GUIDANCE:

Tandem Diabetes sees FY2016 revenue of $105-112 million, versus the consensus of $102.5 million.

• Operating margin is estimated to be in the range of negative 55 percent to negative 65 percent, which includes

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.